Vitamin D and diabetes: Where do we stand?

Diabetes Research and Clinical Practice

Volumn 108, Issue 2, 2015, Pages 201-209

  Mathieu, Chantal ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Clinical and experimental endocrinology

Indexed keywords

CALCIFEDIOL; CALCITRIOL; CYTOKINE; VITAMIN D; VITAMIN D RECEPTOR; 1,25-DIHYDROXYVITAMIN D;

CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; EPIDEMIOLOGICAL DATA; GENETIC VARIABILITY; GLYCEMIC CONTROL; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; ANALOGS AND DERIVATIVES; ANIMAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIET SUPPLEMENTATION; DISEASE MODEL; DOSE RESPONSE; EPIDEMIOLOGY; RISK FACTOR;

ANIMALS; CAUSALITY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84927913107     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.01.036     Document Type: Review

References (71)

1. Ross A.C., Manson J.E., Abrams S.A., Aloia J.F., Brannon P.M., Clinton S.K., et al. The 2011 dietary reference intakes for calcium and vitamin d: what dietetics practitioners need to know. J Am Diet Assoc 2011, 111:524-527.
2. Bikle D.D. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol 2014, 21:319-329.
3. Stoffels K., Overbergh L., Giulietti A., Verlinden L., Bouillon R., Mathieu C. Immune regulation of 25-hydroxyvitamin-D3-1alpha-hydroxylase in human monocytes. J Bone Miner Res 2006, 21:37-47.
4. Muscogiuri G., Mitri J., Mathieu C., Badenhoop K., Tamer G., Orio F., et al. Mechanisms in endocrinology: vitamin D as a potential contributor in endocrine health and disease. Eur J Endocrinol 2014, 171:R101-R110.
5. Chang-Chen K.J., Mullur R., Bernal-Mizrachi E. Beta-cell failure as a complication of diabetes. Rev Endocr Metab Disord 2008, 9:329-343.
6. Cnop M., Foufelle F., Velloso L.A. Endoplasmatic reticulum stress, obesity and diabetes. Trends Mol Med 2012, 18:59-68.
7. Donath M.Y. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov 2014, 13:465-476.
8. Takiishi T., Gysemans C., Bouillon R., Mathieu C. Vitamin D and diabetes. Rheum Dis Clin N Am 2012, 38:179-206.
9. Luca G., Nastruzzi C., Basta G., Brozzetti A., Saturni A., Mughetti D., et al. Effects of anti-oxidizing vitamins on in vitro cultured porcine neonatal pancreatic islet cells. Diabetes Nutr Metab 2000, 13:301-307.
10. Cheng Q., Li Y.C., Boucher B.J., Leung P.S. A novel role for vitamin D: modulation of expression and function of the local renin-angiotensin system in mouse pancreatic islets. Diabetologia 2011, 54:2077-2081.
11. Riachy R., Vandewalle B., Kerr Conte J., Moerman E., Sacchetti P., Lukowiak B., et al. 1,25-dihydroxyvitamin D3 protects RINm5F and human islet cells against cytokine-induced apoptosis: implication of the antiapoptotic protein A20. Endocrinology 2002, 143:4809-4819.
12. Mauricio D., Andersen H.U., Larsen C.M., Karlsen A.E., Mandrup-Poulsen T., Nerup J. Dexamethasone prevents interleukin-1 beta-mediated inhibition of rat islet insulin secretion without decreasing nitric oxide production. Cytokine 1997, 9:563-569.
13. Wolden-Kirk H., Rondas D., Bugliani M., Korf H., Van Lommel L., Brusgaard K., et al. Discovery of molecular pathways mediating 1,25-dihydroxyvitamin D3 protection against cytokine-induced inflammation and damage of human and male mouse islets of Langerhans. Endocrinology 2014, 155:736-747.
14. Gysemans C.A., Cardozo A.K., Callewaert H., Giulietti A., Hulshagen L., Bouillon R., et al. 1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice. Endocrinology 2005, 146:1956-1964.
15. Riachy R., Vandewalle B., Moerman E., Belaich S., Lukowiak B., Gmyr V., et al. 1,25-Dihydroxyvitamin D3 protects human pancreatic islets against cytokine-induced apoptosis via down-regulation of the Fas receptor. Apoptosis 2006, 11:151-159.
16. Maestro B., Dávila N., Carranza M.C., Calle C. Identification of a vitamin D response element in the human insulin receptor gene promoter. J Steroid Biochem Mol Biol 2003, 84:223-230.
17. George N., Peeyush K.T., Antony S., Paulose C.S. Effect of vitamin D3 in reducing metabolic and oxidative stress in the liver of streptozotocin-induced diabetic rats. Br J Nutr 2012, 702:1-9.
18. Calle C., Maestro B., Garcia-Arencibia M. Genomic actions of 1,25-dihydroxyvitamin D3 on insulin receptor gene expression, insulin receptor number and insulin activity in the kidney, liver and adipose tissue of streptozotocin-induced diabetic rats. BMC Mol Biol 2008, 9:65.
19. Zhou Q.G., Hou F.F., Guo Z.J., Liang M., Wang G.B., Zhang X. 1,25-Dihydroxyvitamin D improved the free fatty-acid-induced insulin resistance in cultured C2, C12 cells. Diabetes Metab Res Rev 2008, 24:459-464.
20. 2+ and AMPK both mediate stimulation of glucose transport by muscle contractions. Diabetes 2004, 53:330-335.
21. Dunlop T.W., Väisänen S., Frank C., Molnár F., Sinkkonen L., Carlberg C. The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor. J Mol Biol 2005, 349:248-260.
22. Gao D., Trayhurn P., Bing C. 1,25-Dihydroxyvitamin D(3) inhibits the cytokine-induced secretion of MCP-1 and reduces monocyte recruitment by human preadipocytes. Int J Obes (Lond) 2012, 37:357-365.
23. Mutt S.J., Hyppönen E., Saarnio J., Järvelin M.R., Herzig K.H. Vitamin D and adipose tissue-more than storage. Front Physiol 2014, 5:228.
24. Behall K.M., Scholfield D.J., Hallfrisch J.G., Kelsay J.L., Reiser S. Seasonal variation in plasma glucose and hormone levels in adult men and women. Am J Clin Nutr 1984, 40:1352-1356.
25. Lindqvist P.G., Olsson H., Landin-Olsson M. Are active sun exposure habits related to lowering risk of type 2 diabetes mellitus in women, a prospective cohort study?. Diabetes Res Clin Pract 2010, 90:109-114.
26. Pittas A.G., Lau J., Hu F.B., Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007, 92:2017-2029.
27. Mitri J., Pittas A.G. Vitamin D and diabetes. Endocrinol Metab Clin N Am 2014, 43:205-232.
28. Ortlepp J.R., Metrikat J., Albrecht M., von Korff A., Hanrath P., Hoffmann R. The vitamin D receptor gene variant and physical activity predicts fasting glucose levels in healthy young men. Diabet Med 2003, 20:451-454.
29. Jain R., von Hurst P.R., Stonehouse W., Love D.R., Higgins C.M., Coad J. Association of vitamin D receptor gene polymorphisms with insulin resistance and response to vitamin D. Metabolism 2012, 61:293-301.
30. Kawashima H., Castro A. Effect of 1 alpha-hydroxyvitamin D3 on the glucose and calcium metabolism in genetic obese mice. Res Commun Chem Pathol Pharmacol 1991, 33:155-161.
31. de Souza Santos R., Vianna L.M. Effect of cholecalciferol supplementation on blood glucose in an experimental model of type 2 diabetes mellitus in spontaneously hypertensive rats and Wistar rats. Clin Chim Acta 2005, 358:146-150.
32. Ceylan-Isik A., Hünkar T., Aşan E., Kaymaz F., Ari N., Söylemezoğlu T., et al. Cod liver oil supplementation improves cardiovascular and metabolic abnormalities in streptozotocin diabetic rats. J Pharm Pharmacol 2007, 59:1629-1641. (Antioxidants in Diabetes-Induced Complications) The ADIC Study Group.
33. Pittas A.G., Dawson-Hughes B., Li T., Van Dam R.M., Willett W.C., Manson J.E., et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 2006, 29:650-656.
34. de Boer I.H., Tinker L.F., Connelly S., Curb J.D., Howard B.V., Kestenbaum B., et al. Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. Diabetes Care 2008, 31:701-707. Women's Health Initiative Investigators.
35. Pittas A.G., Dawson-Hughes B., Sheehan P.R., Rosen C.J., Ware J.H., Knowler W.C., et al. Rationale and design of the vitamin d and type 2 diabetes (d2d) study: a diabetes prevention trial. Diabetes Care 2014, 37:3227-3234. D2d Research Group.
36. Van Belle T.L., Gysemans C., Mathieu C. Vitamin D in autoimmune, infectious and allergic diseases: a vital player?. Best Pract Res Clin Endocrinol Metab 2011, 25:617-632.
37. Ferreira G.B., Gysemans C.A., Demengeot J., da Cunha J.P., Vanherwegen A.S., Overbergh L., et al. 1,25-Dihydroxyvitamin D3 promotes tolerogenic dendritic cells with functional migratory properties in NOD mice. J Immunol 2014, 192:4210-4220.
38. Ferreira G.B., van Etten E., Lage K., Hansen D.A., Moreau Y., Workman C.T., et al. Proteome analysis demonstrates profound alterations in human dendritic cell nature by TX527, an analogue of vitamin D. Proteomics 2009, 9:3752-3764.
39. Ferreira G.B., Vanherwegen A.S., Eelen G., Fierro Gutiérrez A.C., Van Lommel L., Marchal K., et al. 1,25-Dihydroxyvitamin D3 generates tolerogenic dendritic cells through activation of glycolysis and the PI3K-Akt-mTOR pathway. Cell Rep 2014, [in press].
40. Unger W.W., Laban S., Kleijwegt F.S., van der Slik A.R., Roep B.O. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur J Immunol 2009, 39:3147-3159.
41. Ferreira G.B., Kleijwegt F.S., Waelkens E., Lage K., Nikolic T., Hansen D.A., et al. Differential protein pathways in 1,25-dihydroxyvitamin d(3) and dexamethasone modulated tolerogenic human dendritic cells. J Proteome Res 2012, 11:941-971.
42. Baeke F., Takiishi T., Korf H., Gysemans C., Mathieu C. Vitamin D and the immune system. Curr Opin Pharmacol 2010, 10:482-496.
43. Baeke F., Korf H., Overbergh L., Verstuyf A., Thorrez L., Van Lommel L., et al. The vitamin D analog, TX527, promotes a human CD4+CD25 highCD127 low regulatory T cell profile and induces a migratory signature specific for homing to sites of inflammation. J Immunol 2011, 186:132-142.
44. Van Belle T.L., Vanherwegen A.S., Feyaerts D., De Clercq P., Verstuyf A., Korf H., et al. 1,25-Dihydroxyvitamin D3 and its analog TX527 promote a stable regulatory T cell phenotype in T cells from type 1 diabetes patients. PLOS ONE 2014, 9:e109194.
45. Rolf L., Muris A.H., Hupperts R., Damoiseaux J. Vitamin D effects on B cell function in autoimmunity. Ann N Y Acad Sci 2014, 1317:84-91.
46. Chen S., Sims G.P., Chen X.X., Gu Y.Y., Chen S., Lipsky P.E. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007, 179:1634-1647.
47. Drozdenko G., Scheel T., Heine G., Baumgrass R., Worm M. Impaired T cell activation and cytokine production by calcitriol-primed human B cells. Clin Exp Immunol 2014, 178:364-372.
48. Van Belle T.L., Gysemans C., Mathieu C. Vitamin D and diabetes: the odd couple Trends. Endocrinol Metab 2013, 24:561-568.
49. Takiishi T., Ding L., Baeke F., Spagnuolo I., Sebastiani G., Laureys J., et al. Dietary supplementation with high doses of regular vitamin D3 safely reduces diabetes incidence in NOD mice when given early and long term. Diabetes 2014, 63:2026-2036.
50. Gregori S., Giarratana N., Smiroldo S., Uskokovic M., Adorini L. A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002, 51:1367-1374.
51. Decallonne B., van Etten E., Overbergh L., Valckx D., Bouillon R., Mathieu C. 1Alpha,25-dihydroxyvitamin D3 restores thymocyte apoptosis sensitivity in non-obese diabetic (NOD) mice through dendritic cells. J Autoimmun 2005, 24:281-289.
52. Casteels K., Waer M., Bouillon R., Depovere J., Valckx D., Laureys J., et al. 1,25-Dihydroxyvitamin D3 restores sensitivity to cyclophosphamide-induced apoptosis in non-obese diabetic (NOD) mice and protects against diabetes. Clin Exp Immunol 1998, 112:181-187.
53. Casteels K., Waer M., Laureys J., Valckx D., Depovere J., Bouillon R., et al. Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic nonobese diabetic mice by a combination of a vitamin D3 analog and cyclosporine. Transplantation 1998, 65:1225-1232.
54. Gysemans C., Van Etten E., Overbergh L., Verstuyf A., Waer M., Bouillon R., et al. Treatment of autoimmune diabetes recurrence in non-obese diabetic mice by mouse interferon-beta in combination with an analogue of 1 alpha,25-dihydroxyvitamin-D3. Clin Exp Immunol 2002, 128:213-220.
55. Gregori S., Casorati M., Amuchastegui S., Smiroldo S., Davalli A.M., Adorini L., et al. T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 2001, 167:1945-1953.
56. Zeitz U., Weber K., Soegiarto D.W., Wolf E., Balling R., Erben R.G. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J 2003, 17:509-511.
57. Mathieu C., Van Etten E., Gysemans C., Decallonne B., Kato S., Laureys J., et al. In vitro and in vivo analysis of the immune system of vitamin D receptor knockout mice. J Bone Miner Res 2001, 16:2057-2065.
58. Gysemans C., van Etten E., Overbergh L., Giulietti A., Eelen G., Waer M., et al. Unaltered diabetes presentation in NOD mice lacking the vitamin D receptor. Diabetes 2008, 57:269-275.
59. Gorham E.D., Garland C.F., Burgi A.A., Mohr S.B., Zeng K., Hofflich H., et al. Lower prediagnostic serum 25-hydroxyvitamin D concentration is associated with higher risk of insulin-requiring diabetes: a nested case-control study. Diabetologia 2012, 55:3224-3227.
60. Munger K.L., Levin L.I., Massa J., Horst R., Orban T., Ascherio A. Preclinical serum 25-hydroxyvitamin D levels and risk of type 1 diabetes in a cohort of US military personnel. Am J Epidemiol 2013, 177:411-419.
61. Hyppönen E., Läärä E., Reunanen A., Järvelin M.R., Virtanen S.M. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001, 358:1500-1503.
62. Stene L.C., Joner G. Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study. Am J Clin Nutr 2003, 78:1128-1134. Norwegian Childhood Diabetes Study Group.
63. Zipitis C.S., Akobeng A.K. Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child 2008, 93:512-517.
64. Stene L.C., Ulriksen J., Magnus P., Joner G. Use of cod liver oil during pregnancy associated with lower risk of Type I diabetes in the offspring. Diabetologia 2000, 43:1093-1098.
65. Sørensen I.M., Joner G., Jenum P.A., Eskild A., Torjesen P.A., Stene L.C. Maternal serum levels of 25-hydroxy-vitamin D during pregnancy and risk of type 1 diabetes in the offspring. Diabetes 2012, 61:175-178.
66. Cooper J.D., Smyth D.J., Walker N.M., Stevens H., Burren O.S., Wallace C., et al. Inherited variation in vitamin D genes is associated with predisposition to autoimmune disease type 1 diabetes. Diabetes 2011, 60:1624-1631.
67. Frederiksen B.N., Kroehl M., Fingerlin T.E., Wong R., Steck A.K., Rewers M., et al. Association between vitamin D metabolism gene polymorphisms and risk of islet autoimmunity and progression to type 1 diabetes: the diabetes autoimmunity study in the young (DAISY). J Clin Endocrinol Metab 2013, 98:E1845-E1851.
68. Walter M., Kaupper T., Adler K., Foersch J., Bonifacio E., Ziegler A.G. No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes. Diabetes Care 2010, 33:1443-1448.
69. Li X., Liao L., Yan X., Huang G., Lin J., Lei M., et al. Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev 2009, 25:411-416.
70. Bock G., Prietl B., Mader J.K., Höller E., Wolf M., Pilz S., et al. The effect of vitamin D supplementation on peripheral regulatory T cells and β cell function in healthy humans: a randomized controlled trial. Diabetes Metab Res Rev 2011, 27:942-945.
71. Rosen C.J., Abrams S.A., Aloia J.F., Brannon P.M., Clinton S.K., Durazo-Arvizu R.A., et al. IOM committee members respond to Endocrine Society vitamin D guideline. J Clin Endocrinol Metab 2012, 97:1146-1152.